Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome.

ABSTRACT:

Background

In 1978, Charlotte Dravet first described a form of epilepsy termed Dravet syndrome (DS). It is a form of genetic epilepsy with early-onset, intractable epilepsy episodes, and neurodevelopmental delay. In children, DS can lead to refractory seizures that are resistant to standard therapy. Recently, perampanel (PER) was approved as an antiepileptic drug for patients as young as 4 years old.

Methods

The medical records were retrospectively reviewed and patients with DS who used PER were included in this study. The diagnosis was established using whole-exome sequencing, and the collected data included the patients' demographic characteristics, seizure pattern, PER dosage, laboratory and imaging findings.

Results

This study included 18 pediatric patients with a

SUBMITTER: Muthaffar OY 

PROVIDER: S-EPMC11071018 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature